Population-based cancer screening recommendations are also suggested for solid organ transplant recipients (SOTR); however, recommendation adherence is unknown. In a population-based cohort of SOTR in Ontario between 1997 and 2010, we determined the uptake of breast, cervical, and colorectal cancer screening tests and identified factors associated with up-to-date screening using recurrent event analysis. We identified 4436 SOTR eligible for colorectal, 2252 for cervical, and 1551 for breast cancer screening. Of those, 3437 (77.5%), 1572 (69.8%), and 1417 (91.4%), respectively, were not up-to-date for cancer screening tests during the observation period. However, these rates are likely an overestimate due to the inability to differentiate between tests done for screening or for diagnosis. SOTR with fewer comorbidities had higher rates of becoming screen up-to-date. Assessment by a primary care provider (PCP) was associated with becoming up-to-date with cancer screening (breast relative risk [RR] = 1.40, 95% confidence interval [CI]: 1.12-1.76, cervical RR = 1.29, 95% CI: 1.06-1.57, colorectal RR = 1.30, 95% CI: 1.15-1.48). Similar results were observed for continuity of care by transplant specialist at a transplant center. In conclusion, cancer screening for most SOTR does not adhere to standard recommendations. Involvement of PCPs in posttransplant care and continuity of care at a transplant center may improve the uptake of screening.
Introduction
An important complication associated with solid organ transplantation is the development of malignancy (1) (2) (3) . Solid organ transplant recipients (SOTR) are at increased risk of developing and dying from malignancies compared to the general population. Cancer is a leading cause of death in this population (4) (5) (6) , and as the management of cardiovascular and infectious diseases improves, the relative burden of cancer mortality in transplant recipients is expected to increase (7) . Several factors have been associated with poor outcomes in SOTR with cancer: malignancies in SOTR tend to be biologically more aggressive (8, 9) , and patients may receive less aggressive cancer treatment due to increased toxicity and coexisting comorbidities (10) .
Although no randomized controlled screening trials have been performed in SOTR (11) , decision modeling studies in the kidney transplant population have shown screening for colon and cervical cancer to be costeffective and for breast cancer similar costs with reduced benefit (12) (13) (14) (15) . Given the available evidence, current recommendations for breast, colorectal, and cervical cancer screening generally parallel the guidelines available for the general population (16) (17) (18) (19) (20) . Adherence to these recommendations among transplant recipients is currently unknown. We therefore designed this study to evaluate the posttransplant screening rates for colorectal, breast, and cervical cancer among SOTR in Ontario, Canada, and to identify factors associated with screening.
Data sources
Our SOTR cohort was assembled using the Canadian Organ Replacement Register (CORR) housed at the Canadian Institute for Health Information. CORR is a national registry that contains information on virtually all Canadian patients who have undergone solid organ transplantation since 1981 (21) . Uptake of cancer screening services was captured using the Ontario Health Insurance Plan (OHIP) database. The OHIP database captures all physician, laboratory, and radiology services provided to Ontario residents since July 1991. Uptake of mammography was augmented with data from the Ontario Breast Screening Program (OBSP) database, including all services related to the provincial breast screening program. Health insurance eligibility and mortality information were obtained from the Registered Persons Database (RPDB). RPDB is a roster of all individuals eligible for OHIP including permanent residents and refugees, which contains vital status information and location of residence. Cancer diagnosis was determined through linkage to the Ontario Cancer Registry (OCR). This registry contains information on all incident cancers since 1964 in Ontario and has been estimated to be over 95% complete (22) . Lastly, the Institute for Clinical Evaluative Sciences (ICES) Physician Database (IPDB) was used to obtain information about physician demographics, specialty training, and practice location in Ontario. All data sources were deterministically linked using encrypted unique direct patient identifiers that allow for longitudinal tracking of patients across all data sources. Direct personal identifiers were removed and a unique identifier was applied using an algorithm. These datasets were linked using unique encoded identifiers and analyzed at ICES, Toronto, Canada.
Study subjects and screening cohorts
All Ontario residents 18 years old and older transplanted for kidney, liver, lung, or heart from January 1, 1997 through December 31, 2010 were included (n = 7994). Patients were excluded if they died (n = 340) or developed a malignancy (n = 173) within a year after transplantation, or had a history of malignancy pretransplantation (n = 793). Additionally, recipients who were not eligible for health insurance for more than 3 months were excluded (n = 296). Women who underwent hysterectomy prior to transplantation were also excluded from the cervical screening cohort. The breast screening cohort included women age 50-74, the cervical screening cohort included women age 21-69, and the colorectal cancer screening cohort included all recipients age 50-74.
Outcome
First, we evaluated the rate of cervical, breast, and colorectal cancer screening among all eligible SOTR. Using the OHIP database, we identified SOTR who underwent a colonoscopy, flexible sigmoidoscopy, fecal occult blood test (FOBT), Pap test, and mammography between January 1, 2000 and December 31, 2013 using billing codes (Appendix S1). Cancer screening tests were identified starting in January 1, 2000 due to availability of test-specific procedure codes in OHIP and establishment of screening programs in Ontario. However, the OHIP billing codes do not distinguish between screening and diagnosis tests. To minimize the inclusion of diagnostic and surveillance tests, patients with prior history of malignancy were excluded, as previously indicated. The main outcome was the rate of SOTR being up-to-date with cancer screening consistent with Ontario guidelines for cancer screening. Cancer screening-specific time frames started when transplant recipients became age-eligible for screening or on the date of the cancer screeningspecific event (if any). Female recipients were considered up-to-date with breast and cervical cancer screening if they received a mammography within 2 years and a Pap test within 3 years, respectively. Transplant recipients were considered up-to-date with colorectal cancer screening if they received a FOBT within 2 years, a flexible sigmoidoscopy within 5 years, or colonoscopy within 10 years. For SOTR who were not adherent with screening at some point during follow-up, we looked for factors associated with the rate of becoming up-to-date with screening, by the type of screening.
Covariates
Transplant recipients' characteristics included age, sex, neighborhood income quintile, and rural residence. Median annual income by neighborhood was determined by using the 2001 or 2006 census data (closest to the index procedure date), which was linked to postal forward sortation areas and categorized into community-specific quintiles within census regions. We used city, postal code, and dissemination area of patient residence to assign rural residence (defined as population <10 000). The Charlson comorbidity score (CCS) was computed for each patient and categorized as no hospitalization, 0, 1, 2, 3, or ≥4 (23). Comorbid conditions were evaluated based on ICD-9 codes for those with hospital discharges within 2 years of the index date (24) . There are six adult transplant centers in the province and each was included as a covariate in the models.
We identified outpatient visits by SOTR with a primary care physician (PCP) or transplant specialist in the year before their transplant and each year following transplant. Information on PCP and specialty training was obtained from the ICES Physician Database. Outpatient visits to PCPs were determined by general assessment OHIP fee codes claimed by general practitioners/family physicians (Appendix S1). Patients were considered to have continuity of care provided by a PCP if they had more than 3 visits to the same PCP within the prior 2-year period. Visits to a transplant specialist were identified using billing codes claimed by a cardiologist for heart transplant recipients, a respirologist for lung transplant recipients, a gastroenterologist or internist for liver transplant recipients, and a nephrologist for kidney transplant recipients (Appendix S1). As the specialty code for nephrologists was not introduced to OHIP until 2009, we identified nephrologists using a predefined algorithm of billing codes for a nephrologist consult and dialysis (Appendix S1) (25) . Visits to a transplant specialist were further categorized as happening at the original transplant center using the institution codes associated with the OHIP billing codes.
Statistical analysis
The chi-square Cochran-Armitage linear trend test was used to assess for time trends in the rates of cancer screening, visits to a PCP, and visits to a transplant specialist (26) . Transplant recipients could be eligible to receive cancer screening multiple times during the observation window. Therefore, we modeled the association between covariates and the rate of becoming up-to-date with cancer screening using an Andersen-Gill (27) recurrent event regression model under a counting process framework (28) . Interval start time was defined for each SOTR on the day when the patient was not up-to-date with screening (meaning they were due for screening) and interval end time was defined when the screening test occurred, or when the patient was censored. Patients were followed from the date of transplantation until the development of a posttransplant de novo malignancy, end of screening eligibility, graft/organ failure, loss of health insurance eligibility, death, or March 31, 2013. For cervical cancer screening, patients were censored at the time of first colposcopy. This provided a minimum of 27 months of follow-up for all cohort members. The concept of discontinuous risk intervals were used to account for the fact that a patient is only "at risk" of becoming up-to-date once they are not up-to-date. A patient who is always up-to-date will, by definition, never contribute any "at risk" intervals to this analysis. We used the Breslow approach to account for ties. To address correlation among screening events from the same patient, robust standard errors of the model parameter estimates were calculated using a sandwich approach (4).
The covariates included in the model were selected a priori. Neighborhood income quintiles, CCS (no hospitalizations, 0, 1, 2, 3, 4 or more), and visits to PCP and transplant specialists (treated as a dichotomous variable) were incorporated into the recurrent event model as timevarying covariates. That is, for each patient, at any given time t, these covariates reflected the exposure in the prior year. The statistical and clinical literature offer several examples on the implementation of such timevarying covariates in a recurrent event model (28) (29) (30) (31) (32) (33) (34) . The multivariable model also adjusted for baseline/time-fixed characteristics at transplantation (age [treated as a continuous variable], sex, transplant year, transplanted organ [kidney, liver, heart, and lung], transplant center [center [1] [2] [3] [4] [5] [6] , rural versus urban residence, and pretransplant continuity of care [within 1 year prior to transplantation] provided by a PCP [treated as a dichotomous variable]). A sensitivity analysis was performed by increasing the screening windows by 6 months for all screening modalities. An additional recurrent event model was created incorporating visits to a transplant specialist at their transplant center (as time-varying dichotomous variable) instead of visits to any transplant specialist to explore the effect of follow-up at their transplant center on becoming up-to-date with screening. All tests were two-sided with a p-value of less than 0.05 considered statistically significant. Analyses were performed using SAS version 9.3 (SAS Institute Inc., Cary, NC).
Results
We identified 6392 SOTR who met our inclusion criteria ( Figure 1 ): 4436 eligible for colorectal cancer screening, 2252 eligible for cervical cancer screening, and 1551 eligible for breast cancer screening. Of those, 3436 (77.5%), 1572 (69.8%), and 1417 (91.4%) were not continuously adherent to recommended colorectal, cervical, and breast cancer screening, respectively, and were included in the multivariable analysis examining factors associated with becoming screen up-to-date. Notably, a sizable proportion of eligible SOTR had no screening during their observation period: 1595 (35.9%), 769 (34.1%), and 477 (30.7%) had no screening for colorectal, cervical, and breast cancer screening, respectively.
The proportion of screening up-to-date recipients increased over time from transplantation for breast (p < 0.001), cervical (p < 0.001), and colorectal (p < 0.001) screening (Figure 2) . Among the SOTR eligible for breast cancer screening, only 36% had a screening mammography during the first year after transplantation. By year 15 after transplantation, 51% of SOTR were up-to-date with breast cancer screening. Similarly, the proportion of SOTR up-to-date with colorectal screening ranged from 35% during the first year after transplantation to 53% at 15 years after transplantation. The proportion of SOTR up-to-date with cervical cancer screening varied, with 51% and 61% of SOTR upto-date with screening at posttransplant year 1 and 15, respectively. The characteristics of the screening-eligible transplant recipients are presented in Table 1 for the overall cohort, for those always up-to-date (not included in the multivariate analysis), and for those with non-up-to-date periods (included in the multivariate analysis). The rates of visits to a PCP and transplant specialist by years after transplantation are shown in Figure 3 . Ever not up-to-date (n = 1,417)
Always up-to-date (n = 680)
Ever not up-to-date (n = 1,572)
Always up-to-date (n = 999)
Ever not up-to-date (n =3.436) One fifth of transplant recipients did not have a general assessment visit to a PCP during the first-year posttransplant, and the rates of these visits decreased over time (80% at 1 year vs. 67% at 15 years, p < 0.001). Although most recipients had a visit with a transplant specialist in the first year posttransplantation (96%), the involvement of transplant specialists also decreased over time (70% at 15 years, p < 0.001). Most visits to a transplant specialist occurred at their transplant center (93.0%) during the first year posttransplant. However, it ranged from 77.7% at 2 years after transplantation to 79.1% at 15 years after transplantation ( Figure S1 ).
Our multivariable analyses related to becoming up-todate with screening are presented in Figure 4 . Figure S3 ).
Discussion
This study is the first to evaluate cancer screening in a population-based cohort of SOTR. Cancer screening 1551 (100) 134 (100) 1417 (100) 2252 (100) 680 (100) 1572 (100) 1551 ( uptake in our cohort was low; most SOTR had periods when they were nonadherent to screening recommendations during follow-up. In fact, many recipients were never screened. Transplant recipients with more comorbidities had lower rates of becoming screen up-to-date, possibly because of a presumed reduced life expectancy. Visits to a PCP but not a transplant specialist were associated with patients becoming up-to-date with all types of cancer screening. However, one fifth of the recipients did not have an assessment visit to a PCP during the first year after transplantation, and the rate decreased over time. SOTR who had a visit to a transplant specialist at their transplant center were more likely to become upto-date with cancer screening.
There are few prior estimates of posttransplant cancer screening uptake in the SOTR population. A populationbased study explored the use of screening mammography in 17 090 women aged 50 years or older who started dialysis in 1997, using the US Renal Data System (35) . This study found a 25% rate of biennial screening mammography in this population. However, women who were on the transplant list had higher screening rates (69%) (35) . Similar patterns were observed in a population-based cohort of women with chronic kidney disease in Ontario between 2002 and 2013 (36). The incidence of breast cancer screening was 26% for women on dialysis and similar rates were observed for cervical cancer screening (36) . These findings are in sharp contrast to the rates of posttransplant breast cancer screening observed in our population, which was never higher than 50% of age-eligible women. A population-based study assessed the uptake of cervical cancer screening by kidney transplant recipients over a 10-year period in Northern Ireland and reported that only 10% of these patients had the recommended number of screening procedures (37) . In contrast, the rates of posttransplant cervical cancer screening observed in our population were never lower than 51%.
Evidence of the efficacy of cancer screening in SOTR is limited; randomized controlled screening trials have not been performed in this population and are unlikely to be undertaken because of major feasibility issues (17) . Extrapolation from the general population and decisionanalysis studies provide the best guidance to formulate recommendations. Modeling studies have demonstrated that screening for breast, colorectal, and cervical cancer following the recommendations for the general population would be cost-effective in the kidney transplant population (38, 39) . Although such studies have not been conducted in other SOTR populations, similar recommendations are included in clinical practice guidelines for posttransplant care of these recipients. It is important to note that recipients with a decreased life expectancy (less than 5-10 years), such as those with many comorbidities or with failing transplants, are unlikely to benefit from screening (15, 38, 39) .
Rates of individuals up-to-date with cancer screening were lower in SOTR compared to those reported for the general Ontario population. In a population-based cohort study of patients identified as screen-eligible in 2009 living in Ontario, Canada, the screening prevalence was 61.6% (95% CI: 61.4-61.9) for FOBT or endoscopy, 63.4% (95% CI: 63.2-63.7) for Pap smears, and 59.9 (95% CI: 59.6-60.0) for mammograms (40) . The rates of being up-to-date for SOTR varied with time since transplantation; however, at no point were the rates in this group as high as that reported in the general population of Ontario during this time period (40) . Although there is evidence that cancer screening rates are reduced in patients with other chronic diseases (e.g. patients with obesity and diabetes) (41), the screening uptake in SOTR is lower than that observed in these populations (42) (43) (44) . Chan et al reported that between 1999 and 2010, only 60.3% of eligible women with diabetes in Ontario had a screening mammography compared to 65.8% of women without diabetes (44) . In contrast, the highest rate of eligible SOTR up-to-date with breast cancer screening was 51% at year 15 after transplantation.
Most SOTR in our cohort were followed regularly at their transplant center. Although approximately 15% were transferred to the care of a transplant specialist not at their transplant center during the first year of transplantation, the proportion of SOTR seen at their transplant center by a transplant specialist remained stable during the duration of the cohort follow-up. Visits to a transplant specialist at their transplant center were associated with becoming up-to-date with cancer screening. This finding highlights the importance of continuity of care, both with PCP and transplant specialist, for the uptake of cancer screening in SOTR. Coordination of transfer of care between transplant specialist during the first year after transplantation and involvement of PCP are strategies that could improve the uptake of cancer screening.
Screening for malignancies in SOTR is generally considered to be a component of primary care. A survey of liver units in the United States indicated that hepatologists believe PCPs should be involved in the management of non-liver-related transplant complications (45, 46) . Most respondents to the survey stated that responsibility for the overall care of patients beyond 1 year after transplantation predominantly belonged to the PCP. However, the survey also reported that the majority of hepatologists felt that the involvement of PCP occurred infrequently and only 35.8% were satisfied with the PCPs' level of involvement (45) . The American Transplant Society has developed guidelines for the long-term management of the liver transplant recipients directed to PCP. These guidelines recommend that the screening for most malignancies in transplant recipients should be performed at the appropriate sex, age, and frequency as per the American Cancer Society guidelines for the general population (20) . However, it is likely that PCPs are unaware of guidelines issued by transplant organizations. Our results indicated that visits to a PCP were associated with a higher rate of becoming up-to-date with screening. Visits to a PCP have been previously associated with the uptake of cancer screening, especially in the elderly (47, 48) . Therefore, it is important to increase the involvement of PCPs in posttransplant care and increase their awareness of the recommendations for cancer screening in this population.
The major strengths of this study are its populationbased nature and the completeness of the billing claims for the use of screening tests since Ontario is a singlepayer system. In addition, our analytical approach was well suited to explore factors associated with screening events as these have discontinuous risk intervals, and it represents a novel approach to the study of factors associated with repeated screening events. Moreover, although the Andersen-Gill recurrent event model requires forming complex data structures, it easily allows for the incorporation of time-dependent variables.
It is important to note that using the billing codes for screening test from the OHIP database has some limitations, including the inability to differentiate between tests done for screening or for diagnosis. Thus, we have likely overestimated the rate of screening in this population. Although strict screening intervals were employed in this analysis to define patients being up-to-date, a sensitivity analysis increasing the screening interval by 6 months did not alter our findings. Another limitation of this study is the difficulty disentangling the role of transplant specialists versus PCP. Transplant specialists may have prompted patients to request cancer screening from their PCP, but this could not be inferred from the data since the screening event occurred after the PCP visit at which the patient made the request. Transplant specialists may have counseled patients to routinely to request cancer screening as per general population guidelines from their PCP. In addition, it is possible that covariate selection and model misspecification might lead to residual confounding. Lastly, although our findings' generalizability to other countries is potentially limited, lower screening uptake could be expected in healthcare systems without universal access.
In conclusion, cancer screening of SOTR in Ontario is low. Assessment by a PCP was associated with a higher rate of SOTR becoming up-to-date with cancer screening. Continuity of care, both for PCP and transplant programs, is associated with the uptake of cancer screening in SOTR. Increasing knowledge of cancer screening among PCPs and their involvement in posttransplant care could improve the uptake of the cancer screening recommendations. Moreover, enhancing communication between PCP and transplant specialist may help improve cancer screening. A framework to guide individualized cancer screening decisions in SOTR is needed.
Supporting Information
Additional Supporting Information may be found in the online version of this article. Figure S1 : Posttransplant visits to a transplant specialist and a transplant specialist at a transplant center by year since transplantation for all patients eligible for cancer screening. Figure S2 : Multivariable recurrent event analysis for recipients not up-to-date with cancer screening including visit to a transplant specialist at a transplant center. Figure S3 : Sensitivity analysis extending screening windows by 6 months-Multivariable recurrent event analysis for recipients not up-to-date with cancer screening.
Appendix S1: OHIP Fee codes.
To complete the MOC activity associated with this article and earn credit, please go to https://ASTS.org/MOC
